ClinicalTrials.gg
TerminatedNCT05860894PIAFUpdated Oct 22, 2026

Post Intensive Care Unit Atrial Fibrillation

An interventional study of Implantable ECG holter device (Biomonitor3, Biotronik) in Atrial Fibrillation and Critical Illness, sponsored by Centre Hospitalier Universitaire de Besancon. Terminated at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-22.

Sponsored by Centre Hospitalier Universitaire de Besancon · Not applicable, Interventional, and Diagnostic

How we know

Why this study was terminated
Insufficient recruitment
Updated Oct 22, 2026Now TerminatedPrimary completion moved+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
150
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 317 studies in Atrial Fibrillation with a site in France — 63 open to participants now, 87 under way, 5 of them phase 3. Atrial Fibrillation · France.

Enrollment
120th of 193
150 · median 250
Started
2023
with 21 others
No phase
117 of 317
32 open now
Registered
251st of 317
by date

Among the 317 studies in Atrial Fibrillation with a site in France, this one is the 120th largest by enrollment of the 193 interventional ones that give a count, is one of 22 that started in 2023, is one of 117 with no phase, and was the 251st registered.

Atrial Fibrillation

4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.

Browse Atrial Fibrillation studies →

Open to participants now

63 of the 317 studies in Atrial Fibrillation with a site in France are open now. Recruiting first, the newest first:

58 more — sign in →

All 63 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 317 studies in Atrial Fibrillation with a site in France, or all of them as a file.
02

Study summary

Atrial fibrillation (AF) is a common heart rhythm disorder in the intensive care unit (ICU). It can be precipitated by multiple factors but it is unclear whether AF persists after discharge from the ICU, and long term. This study will investigate whether AF recurs up to one year after ICU discharge.

Read the detailed description

Atrial fibrillation (AF) is the most common heart rhythm disorder encountered in the intensive care unit (ICU). It can be precipitated by multiple factors present in critically ill patients, such as tissue hypoxia, metabolic disorders etc. There is a paucity of data regarding the persistence of AF in these patients after discharge from the ICU, and in the longer term. Therefore, this study will investigate whether AF recurs up to one year after ICU discharge using an implantable ECG Holter device in adult patients discharged alive from the ICU, with documented new onset AF.

03

Conditions studied

  • Atrial Fibrillation
  • Critical Illness

Keywords

  • intensive care unit
  • atrial fibrillation
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age >18 years
  • New onset atrial fibrillation diagnosed in the ICU (12 lead or documented episode of atrial fibrillation lasting at least 30 seconds)
  • Patient hospitalized in the ICU with at least one of the following two criteria:

    • orotracheal intubation for mechanical ventilation
    • AND/OR treatment with amines (vasopressors or inotropic agents)
  • Written
  • Patient affiliated to a social security regime (or beneficiary thereof)

Exclusion criteria

Exclusion Criteria:

  • Documented history of atrial fibrillation
  • patients admitted to the ICU after cardiothoracic surgery
  • Patients with \<12 months
  • Patients under legal or judicial protection
  • Patients with no social security coverage
  • Patients within the exclusion period of another clinical trial
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
150 participants (actual)

Study arms

  • Experimental
    Implantable ECG holter device

    Adult patients with new onset atrial fibrillation occuring in the ICU will be implanted with an implantable ECG holter device (Biomonitor3, Biotronik) to monitor arrhythmia episodes up to 2 years after ICU discharge.

    Device: Implantable ECG holter device (Biomonitor3, Biotronik)

Interventions

  • DeviceImplantable ECG holter device (Biomonitor3, Biotronik)

    Subcutaneous implantation of ECG holder device to monitor ECG

06

What researchers measure

Primary outcomes

  1. Rate of recurrence of atrial fibrillation

    Any episode of atrial fibrillation, atrial tachycardia or atrial flutter lasting at least 1 minute, as documented on the implantable device recordings

    Time frame: up to 1 year after ICU discharge

Secondary outcomes

  1. Burden of atrial fibrillation in absolute value

    Burden of atrial fibrillation assessed as time (in days, hours and minutes), expressed as a absolute value

    Time frame: up to 2 years after ICU discharge

  2. Burden of atrial fibrillation (percentage of time spent in atrial fibrillation)

    Burden of atrial fibrillation assessed as time (in days, hours and minutes) expressed as a percentage time spent in atrial fibrillation

    Time frame: up to 2 years after ICU discharge

  3. Rate of Stroke

    Ischemic or hemorrhagei stroke documented by imaging, major bleeding (ISTH classification) or documented peripheral emboli

    Time frame: up to 2 years after ICU discharge

  4. Number of participants with Change in treatment

    Changes in treatment due to the discovery of atrial fibrillation

    Time frame: up to 2 years after ICU discharge

07

Study locations

1 site
  • Centre Hospitalier Universitaire de Besancon
    Besançon, 25000, France
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Sep 2023 to primary completion in Apr 2025, 18 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 22, 2026: primary completion Dec 2026 → Apr 2025 and completion Dec 2026 → Apr 2025.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 27, 2023
First posted
May 16, 2023
StartActual
Sep 19, 2023
Primary completionActual
Apr 10, 2025was Dec 2026
CompletionActual
Apr 10, 2025was Dec 2026
Last update
Oct 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Terminated Insufficient recruitment
changed Oct 22, 2026
Sites
1 site added, 1 site removed
Show site
  • Centre Hospitalier Universitaire de Besancon · Besançon, France
Show 1 removed
  • Centre Hospitalier Universitaire de Besancon · Besancon, France
Oct 22, 2026
Primary completion
Dec 31, 2026→Apr 10, 2025 (actual)
Oct 22, 2026
Study completion
Dec 31, 2026→Apr 10, 2025 (actual)
Oct 22, 2026
Show all 1 update
  1. Oct 22, 2026
    Recruiting→Terminated
    Why stopped Insufficient recruitment
    1 site added, 1 site removed
    Show site
    • Centre Hospitalier Universitaire de Besancon · Besançon, France
    Show 1 removed
    • Centre Hospitalier Universitaire de Besancon · Besancon, France
    Primary completion Dec 31, 2026→Apr 10, 2025 (now actual)
    Study completion Dec 31, 2026→Apr 10, 2025 (now actual)
    + 3 other changes: verification date, contact details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05860894
Responsible party
Sponsor
First posted
May 16, 2023
Start date
Sep 19, 2023
Primary completion
Apr 10, 2025
Completion
Apr 10, 2025
Last update
Oct 22, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion